Avidity Biosciences, Inc. entered into a research collaboration with MyoKardia, to demonstrate the potential utility of AOCs in cardiac tissue by leveraging MyoKardia's genetic cardiomyopathy platform including, among other aspects, its novel target discovery engine and proprietary cardiac disease models.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.45 USD | +3.40% | +8.58% | +192.27% |
04/04 | Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing | MT |
04/04 | Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+192.27% | 2.53B | |
-3.73% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. Enters into A Research Collaboration with MyoKardia